AJP - Heart and Circulatory Physiology, Vol 272, Issue 5 2139-H2145, Copyright © 1997 by American Physiological Society

ARTICLES

Chronic effects of ANG II antagonist in heart failure: improvement of cGMP generation from ANP

Y. Maeda, A. Wada, T. Tsutamoto, D. Fukai and M. Kinoshita
First Department of Internal Medicine, Shiga University of Medical Science, Ohtsu, Japan.

To evaluate the effects of endogenous angiotensin II (ANG II) on the development of congestive heart failure (CHF), we examined cardiorenal and hormonal factors after chronic administration of the ANG II type 1 receptor antagonist TCV-116 in dogs with CHF induced by rapid right ventricular pacing. After 8 days of pacing, TCV-116 administration [1 (group 1) or 3 mg.kg-1.day-1 (group 2)] was started and continued until the 22nd day. TCV-116 was found to have protected the deterioration of cardiorenal functions and the activation of neurohormonal factors. Although there was no significant difference in the pulmonary capillary wedge pressure or plasma atrial natriuretic peptide (ANP) level between the TCV-116-treated groups (354 +/- 85 and 364 +/- 29 pg/ml for groups 1 and 2, respectively) and the vehicle group (385 +/- 20 pg/ml), the plasma guanosine 3',5'-cyclic monophosphate (cGMP) levels, a second messenger of ANP, were twofold higher in TCV-116-treated groups (49.4 +/- 10.2 and 50.6 +/- 7.7 pmol/ml for groups 1 and 2, respectively) than in the vehicle group (24 +/- 4.0 pmol/ml), with a high correlation between the plasma ANP and cGMP levels (r = 0.90; P < 0.05). These findings indicate that endogenous ANG II has important roles in hemodynamics and renal functions during the development of CHF, which may be due, in part, to a reduction in endogenous ANP activity, suggesting the usefulness of an ANG II-receptor antagonist against the development of CHF.

This article has been cited by other articles:

				K. Funabiki, K. Onishi, K. Dohi, T. Koji, K. Imanaka-Yoshida, M. Ito, H. Wada, N. Isaka, T. Nobori, and T. Nakano Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2487 - H2492. [Abstract] [Full Text] [PDF]

				L. G. MELO, M. E. STEINHELPER, S. C. PANG, Y. TSE, and U. ACKERMANN ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models Physiol Genomics, June 29, 2000; 3(1): 45 - 58. [Abstract] [Full Text] [PDF]

				L. G. Melo, A. T. Veress, C. K. Chong, U. Ackermann, and H. Sonnenberg Salt-sensitive hypertension in ANP knockout mice is prevented by AT1 receptor antagonist losartan Am J Physiol Regulatory Integrative Comp Physiol, September 1, 1999; 277(3): R624 - R630. [Abstract] [Full Text] [PDF]

				P. F. Mento, M. E. Pica, J. Hilepo, J. Chang, L. Hirsch, and B. M. Wilkes Increased expression of glomerular AT1 receptors in rats with myocardial infarction Am J Physiol Heart Circ Physiol, October 1, 1998; 275(4): H1247 - H1253. [Abstract] [Full Text] [PDF]

				S. Brodsky, K. Gurbanov, Z. Abassi, A. Hoffman, R. R. Ruffolo Jr, G. Z. Feuerstein, and J. Winaver Effects of Eprosartan on Renal Function and Cardiac Hypertrophy in Rats With Experimental Heart Failure Hypertension, October 1, 1998; 32(4): 746 - 752. [Abstract] [Full Text] [PDF]